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To the Editor
The use of fertility-enhancing therapies, including assisted reproductive technologies (ART), 
has more than doubled in the United States between 1996 and 2005.1 Approximately 1.4% 
of United States live births and 4.3% of Massachusetts live births are conceived using 
ART.2 Several studies have noted an increased risk of birth defects in ART pregnancies 
compared with spontaneous pregnancies.3,4
Previous attempts to validate maternal self-reported ART have shown mixed results. A 
Danish study demonstrated sensitivity of 83% for assisted conception.5 However, maternal 
self-report in the Pregnancy Risk Assessment Monitoring System in the United States 
overestimated ART use when compared with clinic-reported data.6
We compared self-reported ART use among Massachusetts participants in the National Birth 
Defects Prevention Study (NBDPS) with data from ART clinics. The NBDPS is a 
population-based, multi-center case-control study of birth defects, with exposure 
information collected by maternal interview.3, 7 The Society for Assisted Reproductive 
Technology (SART) collects ART procedure information from clinics, providing a gold 
standard for comparison with self-reported information. The SART database contains 
information from over 91% of ART clinics in the United States, with validation conducted 
annually.2 All Massachusetts ART clinics report to SART. SART records have been linked 
to vital records for Massachusetts deliveries as part of a project to evaluate ART outcomes.8
Massachusetts NBDPS participants with in-state deliveries between September 2004 and 
December 2008 were matched to SART records by delivery date, birth/fetal death certificate 
number, and birth outcome. Sensitivity and specificity were calculated to measure accuracy 
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of self-reported ART use among NBDPS participants compared with use recorded in SART. 
Variables compared include in-vitro fertilization (IVF), intracytoplasmic sperm injection 
(ICSI), use of donor eggs, frozen eggs or embryos (frozen cycle), and presence of multiple 
fetuses on ultrasound. The NBDPS did not collect ICSI information until 2006, so these 
analyses are restricted to 2006-2008 deliveries.
Of 1,452 Massachusetts NBDPS participants with in-state deliveries during the study period, 
77 (5.3%) matched to a record in the SART database. Four NBDPS subjects who reported 
IVF or ICSI did not match to a SART record, possibly because of misreporting or because 
ART had been performed out-of-state.
Among NBDPS subjects who matched to SART records, specificity was 87% or greater for 
all procedures and outcomes examined. Sensitivity was 91% for IVF use and did not differ 
by case-control status. Sensitivity was 100% for use of frozen cycle and presence of multiple 
fetuses. Sensitivity was lower for ICSI (71%) and donor egg use (67%), although the 
number of donor egg cycles was small. Sensitivity for ICSI use was 82% among 20 subjects 
interviewed at less than 9 months following delivery, compared with 60% among 24 
subjects interviewed at 9 months or more. ICSI sensitivity was 80% among 37 cases vs. 50% 
among 7 controls (data not shown).
To our knowledge, this is the first study to validate maternal ART exposure information in 
the NBDPS. The study's main strength is its use of validated ART clinic data, providing a 
gold-standard for comparison with maternal self-report. Limitations include small numbers 
for several ART procedures and within subgroups. Also, we could evaluate only 
Massachusetts residents. However, although Massachusetts residents comprise only 12% of 
NBDPS subjects, they account for roughly 40% of all study subjects who report a fertility 
procedure.
Among deliveries to NBDPS subjects who matched to SART records, self-reported use of 
IVF and several other ART procedures and outcomes demonstrated good agreement with 
clinic data, while use of ICSI and donor eggs was underreported. Future studies need to 
validate ART exposure with larger sample sizes, including subjects from other states. These 
results increase confidence in observed associations between ART and birth defects3 in the 
NBDPS.
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